UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000051988
Receipt number R000059331
Scientific Title Neuromyelitis optica spectrum disorder Registry (Japan Neuroimmune Disease Registry)
Date of disclosure of the study information 2023/12/01
Last modified on 2023/08/25 15:50:39

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Neuromyelitis optica spectrum disorder Registry (Japan Neuroimmune Disease Registry)

Acronym

JANIMA

Scientific Title

Neuromyelitis optica spectrum disorder Registry (Japan Neuroimmune Disease Registry)

Scientific Title:Acronym

JANIMA

Region

Japan


Condition

Condition

Neuroimmune Disease (Neuromyelitis Optica Spectrum Disorders, MOG antibody-associated disease)

Classification by specialty

Neurology

Classification by malignancy

Others

Genomic information

YES


Objectives

Narrative objectives1

We will clarify the natural history and prognostic factors of NMOSD and MOGAD by accumulating and reviewing clinical information over a long period of time.

Basic objectives2

Others

Basic objectives -Others

We will establish a system to enable efficient recruitment of patients for clinical trials. This will contribute to the development and establishment of new treatment methods for NMOSD and MOGAD in the future.

Trial characteristics_1


Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

The course of clinical endpoints mainly used for each neuroimmune disease.

Key secondary outcomes

1. Severity (EDSS, Functional Score, mRS)
2. Presence or absence of recurrence and timing
3. Cerebrospinal fluid findings, imaging (MRI) findings
4. Treatment history
5. Adverse events
6. EQ-5D-5L survey


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

As follows:

Neuromyelitis Optica Spectrum Disorder (NMOSD)
1) Patients who meet the Wingerchuk 2015 criteria (International Panel criteria)
2) Patients who have given written consent to participate in the study

Anti-myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)
1) Patients who meet the International Panel 2023 criteria
2) Patients who have given written consent to participate in the study

Key exclusion criteria

Patients deemed inappropriate for inclusion by the investigator.

Target sample size

1000


Research contact person

Name of lead principal investigator

1st name Ichiro
Middle name
Last name Nakashima

Organization

School of Medicine, Tohoku Medical and Pharmaceutical University

Division name

Division of Neurology, Professor

Zip code

9838536

Address

1-15-1 Fukumuro, Miyagino-ku, Sendai, Miyagi Prefecture

TEL

0222908850

Email

nakashima@tohoku-mpu.ac.jp


Public contact

Name of contact person

1st name Juichi
Middle name
Last name Fujimori

Organization

School of Medicine, Tohoku Medical and Pharmaceutical University

Division name

Division of Neurology, Associate Professor

Zip code

9838536

Address

1-15-1 Fukumuro, Miyagino-ku, Sendai, Miyagi Prefecture

TEL

0222908850

Homepage URL

https://www.janima.org

Email

info@janima.org


Sponsor or person

Institute

The Japanese Society for Neuroimmunology

Institute

Department

Personal name



Funding Source

Organization

Chugai Pharmaceutical Co., Ltd.

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Kyoto University Graduate School and Faculty of Medicine, Ethics Committee

Address

Yoshida Konoe-cho, Sakyo-ku, Kyoto

Tel

075-753-4680

Email

ethcom@kuhp.kyoto-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2023 Year 12 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2023 Year 07 Month 24 Day

Date of IRB


Anticipated trial start date

2023 Year 12 Month 01 Day

Last follow-up date

2043 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Personal information, management information, background information, complications, severity at registration, relapse frequency, autoantibody information, cerebrospinal fluid findings, MRI findings, details of treatment


Management information

Registered date

2023 Year 08 Month 23 Day

Last modified on

2023 Year 08 Month 25 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000059331


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name